PT - JOURNAL ARTICLE AU - Esmaeil Mortaz AU - Payam Tabarsi AU - Hamidreza Jamaati AU - Neda Dalil Roofchayee AU - Neda K.Dezfuli AU - Seyed Mohamadreza Hashemian AU - Afshin Moniri AU - Majid Marjani AU - Majid Malkmohammad AU - Davood Mansouri AU - Mohammad Varahram AU - Gert Folkerts AU - Ian M Adcock TI - Increased serum levels of soluble TNF-α receptor is associated with mortality of ICU COVID-19 patients AID - 10.1101/2020.07.12.20152066 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.12.20152066 4099 - http://medrxiv.org/content/early/2020/07/15/2020.07.12.20152066.short 4100 - http://medrxiv.org/content/early/2020/07/15/2020.07.12.20152066.full AB - Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has spread to almost 100 countries, infected over 10M patients and resulted in 505K deaths worldwide as of 30th June 2020. The major clinical feature of severe COVID-19 requiring ventilation is acute Respiratory Distress Syndrome (ARDS) with multi-functional failure as a result of a cytokine storm with increased serum levels of cytokines such as TNF-α and IL-6 being reported. TNF-α levels are increased during the cytokine storm in very ill patients and soluble receptors for IL-6 and IL-2 are present in the blood of COVID-19 patients,Objectives To elucidate the involvement of serum levels of soluble TNF-Receptor of severe and mild COVID-19 patients to determine for severity of disease.Method We recruited16 severe COVID-19 patients in the ICU on ventilator support and 26 milder COVID-19 patients who were hospitalised but not within the intensive care unit (ICU) between March-May 2020 at the Masih Daneshvari Hospital Tehran, Iran. After harvesting of whole blood the serum was isolated and soluble TNF-Receptor levels measured by ELISA.Results Serum levels of the usually inhibitory soluble TNF-α receptor 1 (sTNFαR1) were significantly elevated in severe COVID-19 patients at admission to ICU. High serum levels of sTNFαR1 were associated with mortality of severe COVID-19 patients treated within ICU.Conclusions This pilot study demonstrates for role of STNF-αR1 receptor in severity of disease. Future studies should examine whether lower levels of systemic sTNFαR1 at admission may indicate a better disease outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the authors own funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Ethical committee of Masih Daneshvari Hospital IR.SBMU.NRITLD.REC.1399.123 and consent obtained from study participants was written.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data included in the paper